ProLung

ProLung

Med Tech Company of the Year 2019

ProLung’s mission is to ‘make a difference in time’ for lung cancer patients who face an under-prioritized and highly stigmatized disease that is the leading cause of cancer deaths worldwide. Our patented ProLung Test™ is a predictive analytic designed to determine the risk of malignancy in patients with an indeterminate pulmonary nodule by measuring their unique bioconductance biomarker. ProLung can reduce today’s standard of care from months or years of repeat CT scans to a single day that can help physicians accelerate lung cancer diagnosis from the latest stages of the disease to the earliest where the 5-year survival is 5x higher or 80%.